Along with the identification of common RNA-based alterations associated with certain CNS neoplasms, such as EGFRvIII in IDH-wild type glioblastoma and BRAF-KIAA1549 fusions in pilocytic astrocytoma, we also detected a number of rare fusions in our cohort for which targeted treatments are potentially available [2, 6, 16]. This evidence concerns the gene BRAF and central nervous system neoplasm.